Pharmacovigilance of carbamazepine in the treatment of Central Nervous System conditions
DOI:
https://doi.org/10.46502/issn.2710-995X/2024.11.03Palabras clave:
carbamazepine, Adverse drug reaction, pharmavigilance.Resumen
Anticonvulsants are crucial for treating neurological diseases, necessitating close pharmacovigilance due to their potential risks. For this reason, a prospective descriptive study was conducted to characterize drug-related adverse reactions associated with the use of carbamazepine in the health area of the "Ramon Lopez Peña" Polyclinic, covering the period from July to December 2022. The sample consisted of 35 patients, characterized based on demographic, clinical, and pharmacotherapeutic variables. The detected drug-related adverse events were classified according to causality, severity, and frequency of occurrence. The results showed that the age group of 40-75 years (45.7%) predominated, along with female gender, mixed ethnicity, pre-university education level, and 54.2% did not have any unhealthy habits. The most common diagnosis was epilepsy (68.4%) and among the associated diseases, hypertension was prevalent. The most consumed medications were captopril, hydrochlorothiazide, paracetamol, and metamizole (dipirona). Drug interactions were detected, and 73 adverse reactions occurred, with the nervous system being the most affected at 56.0%. Possible adverse reactions (42.5%), frequent (49.4%), and mild (58.9%) predominated. This study underscores the importance of continuous and effective monitoring in pharmacovigilance to enhance patient safety under carbamazepine treatment, thereby promoting a more rational use of this medication.
Descargas
Citas
Adrián, R. L. (2022, May). Fármaco vigilancia de la Carbamazepina, Policlínico Marta Abreu, Santa Clara 2022. In jorcienciapdcl 2022.
Anderson, M., Egunsola, O., Cherrill, J., Millward, C., Fakis, A., & Choonara, I. (2015). A prospective study of adverse drug reactions to antiepileptic drugs in children. BMJ open, 5(6), e008298.
Balbuena Veliz, F. M., & Damian Ricaldi, M. E. (2018). Incidencia de las Reacciones Adversas Detectadas en Gestantes que fueron Atendidas en el Hospital Regional Docente Materno Infantil “El Carmen” (Tesis de grado), Universidad Privada de Huancayo Franklin Roosevelt.
Barrero Viera, L., & Bestard Pavón, L. A. (2022). La notificación espontánea de las reacciones adversas a medicamentos. Revista cubana de medicina militar, 51(1).
Bihan, K., Lebrun-Vignes, B., Funck-Brentano, C., & Salem, J. E. (2020). Uses of pharmacovigilance databases: an overview. Therapies, 75(6), 591-598.
Bourgeois-Vionnet, J., Ryvlin, P., Elsensohn, M. H., Michel, V., Valton, L., Derambure, P., ... & SAVE study Group. (2022). Coffee consumption and seizure frequency in patients with drug-resistant focal epilepsy. Epilepsy & Behavior, 126, 108486.
Calvo-Salazar, R. A., David, M., Zapata-Mesa, M. I., Rodríguez-Naranjo, C. M., & Valencia-Acosta, N. Y. (2018). Problemas relacionados con medicamentos que causan ingresos por urgencias en un hospital de alta complejidad. Farmacia Hospitalaria, 42(6), 228-233. https://dx.doi.org/10.7399/fh.10996
Choudhury, A., Singh, P. A., Bajwa, N., Dash, S., & Bisht, P. (2023). Pharmacovigilance of herbal medicines: Concerns and future prospects. Journal of Ethnopharmacology, 309, 116383.
Cipolle, R. J., Strand, L.M., & Morley, P.C. (2012). The Patient Centered Approach to Medication Management. En: Pharmaceutical Care Practice. Cipolle RJ, Strand LM, Morley PC. 3rd Edition. New York: McGraw Hill.
Flórez, J., Armijo, J. A., & Mediavilla, Á. (2014). Farmacología humana. Barcelona [etc.]: Elsevier Masson.
García Torres, A. M., & Aldana Becerra, O. E. (2016). Caracterización de eventos adversos y problemas relacionados con Carbamazepina reportados al programa distrital de Farmacovigilancia Bogotá DC 2008-2015. Universidad de Ciencias Aplicadas y Ambientales U.D.C.A. Disponible en: https://repository.udca.edu.co/handle/11158/616
Guarnieri, N. M., Pompilio, A., Marini, C., Ortenzi, G. B., Andresciani, E., Garzone, A. M. F., ... & Polidori, C. (2024). A pharmacovigilance study on antiepileptic medications in a paediatric hospital in Italy. European Journal of Hospital Pharmacy, 31(1), 46-49.
Hariraj, V., Wo, W. K., Lee, S. C., & Ramli, A. (2023). Carbamazepine Induced Severe Cutaneous Adverse Drug Reactions: A 21 Year Comparison Between Children and Adults in Malaysia. The Journal of Clinical Pharmacology, 63(10), 1126-1132.
Hata, M., Tanaka, Y., Kyoda, N., Osakabe, T., Yuki, H., Ishii, I., ... & Hoshino, T. (2008). An epoxidation mechanism of carbamazepine by CYP3A4. Bioorganic & medicinal chemistry, 16(9), 5134-5148
Hernández, Y. S., Avila, D. P., & Vázquez, Y. E. G. (2020). Usos terapéuticos de la carbamazepina en gestantes del Policlínico Alex Urquiola, Holguín, marzo a abril del 2019. Revista Estudiantil HolCien, 1(1).
Ministerio de Salud Pública. (2014). Formulario nacional de medicamentos. 4aEd. Cuba: ENCIMED.
MINSAP. (2020). Anuario Estadístico de Cuba. Estados y datos. Oficina Nacional. Available in: https://instituciones.sld.cu/ucmvc/files/2023/10/Anuario-Estad%C3%ADstico-de-Salud-2022-Ed-2023.pdf
Montastruc, F., & de Laportaliere, T. T. (2024). Drug-induced psychiatric disorders: A pharmacovigilance update. Therapies, 79(2), 173-179.
Mula, M. (2009). New antiepileptic drugs: molecular targets. Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents), 9(2), 79-86.
Narayanan, A. S., Lakshmi, K. S., & Kamaraj, R. (2020). An Overview on Good Pharmacovigilance Practices and New Operational Plan Milestones of Eudravigilance in European Union. Research Journal of Pharmacy and Technology, 13(4), 1795-1800
Noguchi, Y., Takaoka, M., Hayashi, T., Tachi, T., &Teramachi, H. (2020). Antiepileptic combination therapy with Stevens‐Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database. Epilepsia, 61(9), 1979-1989.
Ruíz López, A. (2023). Fármacovigilancia de la carbamazepina en el Policlínico Marta Abreu. Santa Clara, 2022. MediSur, 21(1), 83-89.
Sychev, D. A., Ostroumova, O. D., Pereverzev, A. P., Kochetkov, A. I., Ostroumova, T. M., Klepikova, M. V., ... & Goloborodova, I. V. (2020). Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Pharmateca, 27(6), 113-126. https://doi.org/10.18565/pharmateca.2020.6.113-126
Trabanca Beltrán, Y. A., Jiménez López, G., Alfonso Orta, I., Pavón Guibert, K., & Albear Caró, F. (2018). Implementación del Programa de Notificación de efectos adversos por pacientes en Guantánamo. Revista Información Científica, 97(2), 281-297.
Williams, J. R. (2008). The Declaration of Helsinki and public health. Bulletin of the World Health Organization, 86, 650-652. https://www.scielosp.org/article/bwho/2008.v86n8/650-652
World Health Organization. (2002). The importance of pharmacovigilance. https://www.who.int/publications/i/item/10665-42493
Zabala Arguelles, M. del C. (2021). Los estudios de las desigualdades por color de la piel en Cuba: 2008-2018. Revista Estudios del Desarrollo Social: Cuba y América Latina, 9(1). https://acortar.link/Pdxkhd
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Orange Journal
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
